RE:Insider buys"no insiders have any confidence to buy shares in the open market."
No insiders have feared and sold a single share in going on seven years. Many have continued to add to holdings. The company has ramped up its spending plans to a record ~$6-$7 million for its long standing programs as it continues to invest in the future of these programs. If insiders didn't believe in the programs they could invest elsewhere in their own interest. The Canadian government has been a long standing partner helping to finance certain programs. ~$20 billion market Symrise committed to the new deal last year also spoke about future value. The bioavailability results were a blowout. The avenanthramide clinical trial is about to begin in the next 30 days and a trial program through to preliminary indications of efficacy has been approved by regulators. Dr. Martin Kolb believes if results in mice for the fibrosis product are replicated in humans CZO could change the treatment landscape profoundly.